Compare MYO & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYO | ACIU |
|---|---|---|
| Founded | 2004 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.2M | 213.3M |
| IPO Year | 2017 | 2016 |
| Metric | MYO | ACIU |
|---|---|---|
| Price | $1.06 | $3.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $7.67 | ★ $10.00 |
| AVG Volume (30 Days) | 802.4K | ★ 1.2M |
| Earning Date | 11-10-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $41,643,203.00 | $5,482,957.00 |
| Revenue This Year | $24.07 | N/A |
| Revenue Next Year | $17.48 | $738.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 65.00 | N/A |
| 52 Week Low | $0.71 | $1.43 |
| 52 Week High | $7.17 | $4.00 |
| Indicator | MYO | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 61.37 | 55.61 |
| Support Level | $1.02 | $2.54 |
| Resistance Level | $1.13 | $2.99 |
| Average True Range (ATR) | 0.07 | 0.29 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 77.35 | 50.40 |
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.